Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

NCT05579366 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT05579366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05579366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 7, 2022
Completion date
October 31, 2027
Enrollment
952 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, cervical cancer, endometrial cancer, epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc), fallopian tube cancer, high grade epithelial ovarian cancer, high grade serous ovarian cancer, hormone receptor-positive/her2 negative breast cancer, mesothelioma, non-small cell lung cancer, platinum sensitive ovarian cancer (psoc), platinum-resistant ovarian cancer (proc), primary peritoneal carcinoma, primary refractory ovarian cancer, triple negative breast cancer, uterine cancer